-
公开(公告)号：US20180303841A1
公开(公告)日：2018-10-25
申请号：US15769295
申请日：2016-10-19
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI
CPC classification number: A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14
Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
公开(公告)号：US20170216255A1
公开(公告)日：2017-08-03
申请号：US15488002
申请日：2017-04-14
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/55 , A61K31/4439 , A61K31/325 , A61K31/4155 , A61K31/445 , A61K31/13
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20210009572A1
公开(公告)日：2021-01-14
申请号：US17038917
申请日：2020-09-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D401/06 , C07D405/04 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/13 , A61K31/325 , A61K31/445 , A61K31/55 , A61K31/045 , A61K31/4406
Abstract: The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US20170266162A1
公开(公告)日：2017-09-21
申请号：US15608557
申请日：2017-05-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/55 , A61K31/13 , A61K31/325 , A61K31/4155 , A61K31/445 , A61K31/4439
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20150307451A1
公开(公告)日：2015-10-29
申请号：US14693342
申请日：2015-04-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D209/46 , C07D401/14 , C07D403/04 , C07D401/10 , C07D403/10 , C07D405/14
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
Abstract translation: 本发明提供具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作预防或治疗阿尔茨海默病，精神分裂症，疼痛，睡眠障碍，帕金森病痴呆，路易体痴呆等。 本发明涉及由式（I）表示的化合物或其盐。 其中每个符号如说明书中所述或其盐。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20180162850A1
公开(公告)日：2018-06-14
申请号：US15735418
申请日：2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D413/14 , C07D413/10 , C07D265/22 , C07D417/10 , C07F7/08 , C07D491/107 , A61P25/28
CPC classification number: C07D265/22 , A61P25/28 , C07B2200/07 , C07D413/04 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20180000780A1
公开(公告)日：2018-01-04
申请号：US15685800
申请日：2017-08-24
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/045 , A61K31/4406 , C07D471/04
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170081332A1
公开(公告)日：2017-03-23
申请号：US15311025
申请日：2015-05-15
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Kenichiro SHIMOKAWA , Takuto KOJIMA , Hiroki SAKAMOTO , Ikuo FUJIMORI , Minoru NAKAMURA , Masami YAMADA , Masataka MURAKAMI , Makoto KAMATA , Shinkichi SUZUKI
IPC: C07D487/04 , C07D471/04
CPC classification number: C07D487/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/519 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.
-
公开(公告)号：US20240109874A1
公开(公告)日：2024-04-04
申请号：US18504741
申请日：2023-11-08
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof.
wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US20220411413A1
公开(公告)日：2022-12-29
申请号：US17872680
申请日：2022-07-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D401/06 , C07D405/04 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/13 , A61K31/325 , A61K31/445 , A61K31/55 , A61K31/045 , A61K31/4406
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.034 seconds)
